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In vitro and in vivo effects 
of 3-bromopyruvate against Echinococcus 
metacestodes
Qi Xin1, Miaomiao Yuan1,2, Huanping Li1, Xiaoxia Song1, Jun Lu1 and Tao Jing1* 
Abstract 
While searching for novel anti-echinococcosis drugs, we have been focusing on glycolysis which is relied on by 
Echinococcus for energy production and intermediates for other metabolic processes. The aim of this study was to 
investigate the potential therapeutic implication of glycolytic inhibitors on Echinococcus. Our results demonstrate 
that at an initial concentration of 40 μM, all inhibitors of glycolysis used in the current experiment [3-bromopyruvate 
(3-BrPA), ornidazole, clorsulon (CLS), sodium oxamate and 2,6-dihydroxynaphthalene (NA-P2)] show considerable 
in vitro effects against Echinococcus granulosus protoscoleces and Echinococcus multilocularis metacestodes. Among 
them, 3-BrPA exhibited the highest activity which was similar to that of nitazoxanide (NTZ) and more efficacious than 
albendazole (ABZ). The activity of 3-BrPA was dose dependent and resulted in severe ultrastructural destructions, as 
visualized by electron microscopy. An additional in vivo study in mice infected with E. multilocularis metacestodes 
indicates a reduction in parasite weight after the twice-weekly treatment of 25 mg/kg 3-BrPA for 6 weeks, compared 
to that of the untreated control. In particular, in contrast to ABZ, the administration of 25 mg/kg 3-BrPA did not cause 
toxicity to the liver and kidney in mice. Similarly, at the effective dose against Echinococcus larvae, 3-BrPA showed no 
significant toxicity to human hepatocytes. Taken together, the results suggest that interfering with the glycolysis of 
the parasite may be a novel chemotherapeutical option and 3-BrPA, which exhibited a remarkable activity against 
Echinococcus, may be a promising potential drug against cystic echinococcosis (CE) and alveolar echinococcosis (AE).
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Echinococcosis, caused by the larval stage of the para-
sitic cestode Echinococcus is a serious but neglected hel-
minthic zoonosis. Cystic echinococcosis (CE) caused by 
Echinococcus granulosus is endemic in regions of western 
and central Europe, eastern Europe, North America and 
Asia, particularly in China [1], where CE is endemic in 
at least 23 provinces, with an estimated 380,000 patients 
and nearly 66 million individuals at risk of infection [2, 
3]. Alveolar echinococcosis (AE) caused by Echinococcus 
multilocularis is endemic in the Northern hemisphere, 
and the greatest prevalence is found in Central Asia, 
Russia, north-western China, parts of Europe and Japan 
[4]. A global estimate of AE suggests that approximately 
18,000 (CIs 11,932–28,156) new cases every year and a 
total of 0.3–0.5 million AE cases are diagnosed. Moreo-
ver, most of the disease (over 90%) of AE occurs in west-
ern China [5]. Both diseases are acquired through the 
accidental ingestion of parasite eggs shed by the defini-
tive hosts (mainly dogs for E. granulosus and foxes and 
dogs for E. multilocularis). Upon infection, the larval 
stage of Echinococcus proliferate asexually in humans 
or other intermediate hosts, leading to space-occupying 
lesions, organ malfunction and even death [6].
Currently, percutaneous treatment, surgery and anti-
infective drug treatment are the treatment options for 
CE. Radical surgical resection of the parasitic mass is 
the basis of treatment for AE and accompanied usually 
by chemotherapy. However, in the inoperable and the 
recrudescent patients, chemotherapy is the only option 
[7]. Benzimidazole derivatives such as albendazole (ABZ) 
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and mebendazole are the only two drugs licensed for 
the treatment of human CE and AE [8]. However, the 
cure rate of these drugs against CE was reported to be 
only about 30% and besides, 20–40% of patients do not 
respond favorably. For treating AE, these drugs exhibit 
a parasitostatic rather than parasitocidal effect [9] and 
therefore, the patients have to undergo lifelong applica-
tion of these drugs, which can cause hepatotoxicity. In 
addition, adverse side effects have been observed with 
these drugs [10, 11]. Thus, the development of novel ther-
apeutic drugs for human CE and AE is urgently needed. 
Furthermore, novel parasitocidal drugs might be valu-
able and promising strategies for the control programs 
of CE, which may reduce the viability of protoscoleces in 
infected ungulate hosts and therefore reduce the infec-
tion of dogs.
In the organs of the intermediate host, the parasite, 
especially E. multilocularis metacestodes, exhibit prop-
erties of asexual, unlimited and infiltrative proliferation 
which is similar to malignant tumors. Hence, a num-
ber of antitumor drugs have been investigated in  vitro 
and in vivo and have exhibited promising effects against 
Echinococcus metacestodes and protoscoleces, such as 
2-methoxyestradiol [12], imatinib [13], doxorubicin [14], 
cyclosporine [15], isoflavone genistein and the genistein 
derivative [16], artemisinin and artemisinin derivatives 
[17], tamoxifen [18], bortezomib [19], 5-fluorouracil and 
paclitaxel [20, 21]. Like other parasites, the larval stage 
of Echinococcus obtains glucose from their hosts as their 
energy source. Although E. granulosus and E. multi-
locularis protoscoleces both have aerobic and anaerobic 
respiratory systems, there are no significant differences 
observed in the rate of glycogen utilization under aerobic 
or anaerobic conditions, which indicates that they both 
depend on glycolysis for energy and intermediates pro-
duction [22, 23]. So, the targeting of anaerobic glycolysis 
in Echinococcus and inhibiting the glycolytic enzymes, 
such as hexokinase (HK), glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), fructose 1,6-bisphosphate 
aldolase (ALDO), phosphoglycerate kinase (PGK), phos-
phoglyceratmutase (PGM) and lactate dehydrogenase 
(LDH) may interfere with energy-yielding pathways, 
abolish ATP generation and finally eliminate the Echino-
coccus metacestodes. Several glycolytic inhibiting agents, 
such as 3-bromopyruvate (3-BrPA) [24–26], ornidazole 
[27], clorsulon (CLS) [28], sodium oxamate [29–31] 
and 2,6-dihydroxynaphthalene (NA-P2) [32], have been 
known to abolish ATP generation through glycolysis. 
Accordingly, in the present study, we used a defined 
experimental system to assess the potential therapeutic 
implications based on the metabolic signature of Echi-
nococcus metacestodes by investigating the in  vitro and 
in  vivo effects of glycolytic inhibitors mentioned above 
against E. granulosus and E. multilocularis. Our results 
demonstrate the effective activity of glycolytic inhibitors 
against E. granulosus protoscoleces and E. multilocularis 
metacestodes and 3-BrPA will be a promising drug for 
the treatment of CE and AE.
Materials and methods
Chemicals
ABZ, NTZ, 3-BrPA, ornidazole, CLS, NA-P2, and sodium 
oxamate were obtained from Sigma-Aldrich (St. Louis, 
MO, USA). All tissue culture media and fetal calf serum 
(FCS) were purchased from Hyclone (Logan, UT, USA).
Ethics statement
Animal procedures and management were carried out in 
accordance with the protocols (2014-12-003) approved 
by the Institutional Animal Caring and Using Committee 
of Lanzhou University. Unnecessary animal suffering was 
avoided throughout the study. The animals were housed 
in a temperature-controlled, light-cycled room. Food and 
water were given ad libitum.
In vitro drug treatment of E. granulosus protoscoleces
Echinococcus granulosus protoscoleces were isolated 
aseptically from hydatid cysts in the liver of infected 
sheep slaughtered in an abattoir (Xining, Qinghai, China) 
and washed twice in Hanks balanced salt solution. The 
in vitro drug treatment of protoscoleces was performed 
as previously described [33]. One hundred viable and 
morphologically intact protoscoleces per well were cul-
tured using RPMI 1640 culture medium without FCS and 
phenol red in 24-well tissue culture plates under 37  °C, 
5%  CO2 conditions. All drugs were prepared as stock 
solutions of 20  mM in dimethyl sulfoxide (DMSO) and 
added to the wells to a final concentration of 40 μM for 
initial screening. The drugs showing good efficacy were 
further investigated. For the dose-dependent effects of 
3-BrPA, final concentrations of 10, 20, 40, 60, 80, and 
100  μM were tested. Protoscoleces incubated in culture 
medium containing 0.2% DMSO were used as controls. 
The effect of drugs on the morphology and structural 
integrity of protoscoleces was observed microscopi-
cally every day for a period of 7  days and viability was 
assessed daily by trypan blue staining test. In short, after 
centrifuging at 10 000 × g for 30 s, the precipitated pro-
toscoleces were mixed with 0.04% (w/v) trypan blue for 
3 min. Finally, the mortality rate of the protoscoleces was 
determined under a microscope. Each drug concentra-
tion was performed in duplicate and each experiment 
was repeated twice.
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In vitro drug treatment of E. multilocularis metacestodes
In order to assess in vitro efficacy of the drugs against 
E. multilocularis metacestodes, an in  vitro cultivation 
of E. multilocularis metacestodes (isolate Xinjiang) 
was first carried out as previously described with few 
modifications [34]. In short, metacestodes dissected 
from experimentally infected Mongolian gerbils (Meri-
ones unguiculatus) were cut into small tissue blocks of 
0.5 cm3 and washed twice in Hanks balanced salt solu-
tion. Three pieces of tissue were placed in a 25-cm2 cell 
culture flask containing human liver SMMC-7721 cells 
cultivation medium (Dulbecco modified Eagle medium 
[DMEM], supplemented with 12  mM HEPES, 2  mM 
glutamine, 100  U/mL penicillin, 100  μg/mL strepto-
mycin and 10% FCS). These co-cultures were incu-
bated at 37 °C, 5%  CO2, with medium changes thrice a 
week. The metacestode vesicles were used for in  vitro 
drug efficacy studies when they reached 2 to 4  mm in 
diameter. The metacestode vesicles harvested after 
1–2 months of in vitro culture were washed three times 
in Hanks balanced salt solution and again distributed to 
24-well plates (Corning Inc., New York, NY, USA) with 
approximate 30 vesicles per well. Treatments were car-
ried out in 2  mL of RPMI 1640 culture medium with-
out FCS and phenol red (2  mM glutamine, 100  U/mL 
penicillin, 100 μg/mL streptomycin), in which the drugs 
were added to a final concentration of 40  μM for ini-
tial screening. The drugs showing good efficacy were 
further investigated. For the dose-dependent effects 
of 3-BrPA, final concentrations of 5, 10, 20, 40, 80, 
and 100  μM were tested. Metacestodes incubated in 
culture medium containing 0.2% DMSO were used as 
controls. After 36 and 120  h of incubation, 300  μL of 
culture medium from all groups were collected respec-
tively and centrifuged at 10 000 × g for 30 min at 4 °C. 
The supernatants were recovered and stored at −20 °C 
until measurements of E. multilocularis alkaline phos-
phatase (EmAP) activity.
Determination of EmAP activity
The quantitative assessment of EmAP activity was carried 
out as previously described [35]. The assay was performed 
in 96-well microtiter plates (Corning Inc., New York, 
NY, USA) under axenic conditions. Per well, a 30  μL of 
supernatant aliquot was mixed with 170 μL alkaline phos-
phatase substrate buffer (0.5  M ethanolamine, 0.5  mM 
 MgCl2 [pH 9.8]) containing p-nitrophenyl phosphate 
(1 mg/mL). The plates were incubated at 37 °C for 30 min. 
Then, A405 values were read on an ELISA (enzyme-linked 
immunosorbent assay) reader (Bio-Tek, Winooski, VT, 
USA). The measurements were performed in triplicate.
Ultrastructural investigations of 3‑BrPA treated 
metacestodes
At 120 h of treatment, the metacestodes were fixed and 
processed for scanning electron microscopy (SEM) and 
transmission electron microscopy (TEM). Briefly, the 
metacestodes were fixed in 2.5% glutaraldehyde in PBS 
(pH 7.2) for 24 h at 4 °C, followed by postfixation in 2% 
osmium tetraoxide  (OsO4) in 100 mM PBS (pH 7.2) for 
2 h at room temperature. For SEM analysis, the samples 
were washed in distilled water and dehydrated in vari-
ous concentrations of ethanol (50, 70, 80, 90 and 100%) 
for 10  min at 4  °C. Subsequently, they were immersed 
in 2% isoamyl acetate, dried to a critical point and sput-
ter-coated with gold. Finally, they were observed and 
photographed with a Hitachi S-450 SEM, with an accel-
eration voltage of 30 kV. For TEM analysis, the samples 
were washed in distilled water and treated with 1% ura-
nyl acetate for 1 h. They were then rinsed extensively in 
distilled water, dehydrated in various concentrations of 
ethanol (50, 70, 80, 90 and 100%) and were embedded 
in Epon 812 resin. The embedded samples were dried by 
heat with serial temperatures (40  °C for 48 h and 60  °C 
for 48  h). Then they were cut into ultra-thin sections 
with a LKB-Nova ultramicrotome (LKB, Bromma, Swe-
den), mounted on a copper mesh grid, and stained with 
3% uranyl acetate and lead citrate. Afterwards, the sam-
ples were observed at an acceleration voltage of 80 kV, in 
JEOL JEM-1230 TEM.
Assessment of the efficacy of 3‑BrPA treatment 
in experimentally infected BALB/c mice
3-BrPA was chosen for the in  vivo assessment as it 
exhibited the best effect among selected glycolytic 
inhibitors in the in  vitro experiment. Eight-week-old 
18 to 20 g female BALB/c mice were injected intraperi-
toneally with 200  μL of homogenized E. multilocula-
ris metacestode (isolate Xinjiang) tissue. The animals 
were separated into three groups of seven mice each 
and treatments were carried out as follows: group 1 
received no drugs (200  μL honey/0.5% carboxymethyl 
cellulose (CMC) (1:1 v/v), untreated control group); 
group 2 received ABZ (200  mg/kg/day, ABZ control 
group); group 3 received 3-BrPA (25  mg/kg twice a 
week). The drugs were suspended in honey/0.5% CMC 
(1:1 v/v) and applied orally in a volume of 200  μL/
mouse. The treatments began at 8 weeks post-infection 
and continued for 6  weeks. One week after the treat-
ments stopped, the animals were sacrificed. After nec-
ropsy, the metacestode tissues were carefully isolated 
and recorded, and the parasite weight was determined 
for each animal.
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In vitro toxicity assessment of 3‑BrPA on human 
hepatocytes
The human hepatocytes (7701 cell line) were purchased 
from the Cell Bank of Type Culture Collection Commit-
tee, Chinese Academy of Sciences, Shanghai. The cells 
were seeded into 96-well culture plates at a density of 10 
000 cells/well and incubated in culture medium (RPMI 
1640 containing 2  mM glutamine, 50  U/mL penicillin, 
50 μg/mL streptomycin) for 24 h at 37 °C with 5%  CO2. 
ABZ and 3-BrPA were added to the cultures at concen-
trations of 5, 10, 20, 40, 80, 100, 160 and 200  μM. As 
controls, the cells were performed with medium and 
corresponding amounts of DMSO present in the treated 
groups. After incubation for 48  h, the cell viability was 
examined by the MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) reduction assay [36]. 
A490 values were read on an ELISA reader (Bio-Tek, 
Winooski, VT, USA) and the inhibition rate was calcu-
lated by this formula: [1 − (ODtreated − ODblank)/(ODcon-
trol − ODblank)] × 100%. The  IC50 values were calculated in 
GraphPad Prism 5.
In vivo toxicity assessment in mice
Twenty-one 6 to 8-week-old healthy female BALB/c mice 
were randomly divided into three groups and treatments 
were carried out as follows: group 1 received no drug 
treatment (200 μL honey/0.5% CMC (1:1 v/v), untreated 
control group); group 2 received ABZ (200  mg/kg/day); 
group 3 received 3-BrPA (25  mg/kg twice a week). The 
drugs were suspended in honey/0.5% CMC (1:1 v/v) and 
applied by intragastric inoculation in a volume of 200 μL/
mouse. The treatments were performed for a period of 
6  weeks. At the end of the study, whole blood via ocu-
lar sinus was collected from mice. Serum was separated 
by centrifugation (3000  ×  g, 10  min) following blood 
clotting. The serum levels of alanine aminotransferase 
(ALT), aspartate amino transferase (AST), total protein 
(TP), albumin (ALB), urea, creatinine (CREA), alkaline 
phosphatase (ALP), glutamyltranspeptidase (GGT), total 
bilirubin (TBIL) and direct bilirubin (DBIL) were deter-
mined with an automatic biochemical analyzer (Type 
7170, HITACHI, Ltd., Tokyo, Japan). The mice were 
sacrificed to collect the tissues (liver and kidney). After 
fixation in 10% of neutral formaldehyde for 24 h, the tis-
sues were embedded in paraffin. The samples were then 
sectioned (5 μm thickness) and stained with hematoxylin 
and eosin (HE) [37] for histopathological examination.
Statistics analysis
Statistical analysis was done with SPSS 19.0 software. 
The results are presented as mean ± standard deviation 
(SD). One-way analysis of variance (ANOVA) was used 
to analyze the data on the effects of glycolytic inhibitors 
against E. multilocularis metacestodes. Nonparametric 
test of the Kruskal–Wallis test followed by Dunn multiple 
comparisons test were used for the assessment of efficacy 
of 3-BrPA treatment in the infected BALB/c mice and 
in vivo toxicity assessment in mice. The results are con-
sidered statistically significant for p < 0.05.
Results
In vitro effectivities of the selected glycolytic inhibitors 
against E. granulosus protoscoleces
We investigated the in  vitro effectivities of the selected 
glycolytic inhibitors on E. granulosus protoscoleces in 
comparison to that of NTZ, which served as a positive 
control, using an initial concentration of 40  μM and a 
treatment course of 7 days. Figure 1A shows the results 
of viability assays. The protoscoleces in DMSO con-
trol maintained 100% viability throughout the experi-
mental period. After 7 days of culture, oxamate, NA-P2, 
ornidazole and CLS killed 65%, 76%, 79% and 85% of 
protoscoleces, respectively. Most notable of the drugs 
was 3-BrPA, which exhibited a similar profound activ-
ity against protoscoleces as NTZ, killing 100% of pro-
toscoleces after only 5  days of treatment. Furthermore, 
3-BrPA was subsequently evaluated in a concentration 
series (10, 20, 40, 60, 80 and 100  μM) for a period of 
7 days (Figure 1B). The result demonstrates that 3-BrPA 
exerted a dose- and time-dependent effect against E. 
granulosus protoscoleces. At a concentration of 100, 80, 
60 and 40 μM, 100% protoscoleces were killed within 2, 
3, 4 and 5 days respectively. When tested at a concentra-
tion as low as 10 μM, 3-BrPA could still kill 67% of pro-
toscoleces within 4  days and 84% of the protoscoleces 
within 7 days.
The results of the morphological observation by opti-
cal microscopy coincided with the viability assay as well. 
Figure 1C shows the morphological changes of the proto-
scoleces upon 40 μM 3-BrPA. After 1 day treatment, the 
posterior region of the protoscoleces became contracted 
(Figure  1C (panel c)); after 3  days, the protoscoleces 
exhibited extensive damages, such as collapse of suck-
ers, formation of blebs on the tegument and decrease of 
calcium precipitates (Figure  1C (panel d)); after 5  days, 
the protoscoleces were completely dead with an apparent 
shrinkage of parenchyma (Figure  1C (panel e)). Severer 
morphological alterations were also seen after 5  days 
treatment with NTZ (Figure  1C (panel b)). The proto-
scoleces control maintained a normal morphology (Fig-
ure 1C (panel a)).
In vitro effectivities of the selected glycolytic inhibitors 
against E. multilocularis metacestodes
We investigated the EmAP activity in culture super-
natants at 36 and 120  h following the addition of the 
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Figure 1 In vitro effects of the selected glycolytic inhibitors against E. granulosus protoscoleces. A Protoscoleces were incubated with 
each drug for up to 7 days, and the viability was measured by trypan blue exclusion test. All drugs were applied at a final concentration of 40 μM. B 
Concentration-dependent in vitro anti-protoscoleces effects by 3-BrPA, the most active drug, as a glycolytic inhibitor. Protoscoleces were incubated 
for 7 days with different concentrations (10 to 100 μM). C Light microscopy of protoscoleces incubated with 40 μM NTZ and 3-BrPA respectively. 
(Panel a) Protoscoleces incubated in culture medium containing DMSO served as a control. White arrow with h points towards hooks; (panel b) 
Protoscoleces incubated with NTZ for 5 days; (panel c) Protoscoleces incubated with 3-BrPA for 1 day; (panel d) Protoscoleces incubated with 
3-BrPA for 3 days. Note the formation of blebs on the tegument (black arrow), collapse of suckers and decrease of calcium precipitates; (panel e) 
Protoscoleces incubated with 3-BrPA for 5 days. Note the protoscoleces were completely dead.
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selected glycolytic inhibitors into the culture medium. 
Figure 2A shows the results of EmAP assays carried out 
at an initial concentration of 40 μM. The results demon-
strate that, in comparison to the DMSO control group, 
in  vitro treatment with each of the selected glycolytic 
inhibitors could result in an increased release of AP activ-
ity, which indicates the damage to metacestodes. Obvi-
ously, the exposure for 120  h rendered a higher release 
of the EmAP than that for 36 h, which indicates that the 
effects of the glycolytic inhibitors were stable and time-
dependent. Among the compounds, 3-BrPA resulted in 
0.19 ± 0.05 and 0.44 ± 0.002 OD450  nm increase at 36 
and 120  h of treatment respectively compared with the 
DMSO group, higher than the ABZ group (0.09 ± 0.009; 
0.31 ± 0.002) and other groups except the NTZ group. 
These findings indicate that among these selected glyco-
lytic inhibitors, 3-BrPA exhibited the most active effect 
against E. multilocularis metacestodes. In a subsequent 
experiment at 5, 10, 20, 40, 80 and 100 μM for a period 
of 120  h, it was demonstrated that the effect of 3-BrPA 
against E. multilocularis metacestodes was dose depend-
ent (Figure 2B). In addition, when tested at 5 μM, 3-BrPA 
still showed a high anti-metacestode activity, with a 
0.32 ± 0.001 OD450  nm increase compared with the 
DMSO group, which was also higher than the ABZ group 
(0.31 ± 0.002). The morphological alterations resulting 
from 3-BrPA were also visualized by light microscopy 
(Figure 2C). At 36 h of treatment, the vesicles exhibited 
loss of turgor, collapse of some vesicles, detachment of 
the germinal layer from the laminated layer, and forma-
tion of a densely packed aggregate inside the vesicles.
Ultrastructural alterations of E. multilocularis metacestodes 
after 3‑BrPA treatment
On the basis of anti-Echinococcus effectivities of the 
selected glycolytic inhibitors, the effectivity of 3-BrPA, 
which exhibited the most active effect against E. mul-
tilocularis, was further confirmed on the ultrastruc-
tural level by SEM (Figure  3) and TEM (Figure  4). The 
E. multilocularis metacestodes vesicles in the DMSO 
control exhibited an intact typical structure: the outer 
acellular laminated layer attached closely with the tegu-
ment where many microtriches protruded distinctly 
into the laminated layer, and the germinal layer was sur-
rounded by the laminated layer outside. The inner ger-
minal layer was composed of glycogen storage cells and 
undifferentiated cells (Figures  3A, 4A, B). The metaces-
todes incubated with 40  μM 3-BrPA for 120  h showed 
Figure 2 In vitro effects of the selected glycolytic inhibitors against E. multilocularis metacestodes. A Damage upon vesicles resulted from 
the selected drugs was assessed by measuring the E. multilocularis AP (EmAP) activities in the medium supernatant after 36 and 120 h of in vitro 
treatment. All drugs were added to a final concentration of 40 μM. Vesicles incubated in culture medium containing DMSO served as controls. 
*p < 0.05 vs. ornidazole, clorsulon, sodium oxamate, 2,6-dihydroxynaphthalene, medium and DMSO groups. B In vitro concentration-dependent 
EmAP activities after 120 h incubation with different concentrations (5 to 100 μM) of 3-BrPA. C Visualization of metacestodes after 36 h treatment of 
40 μM 3-BrPA. (Panel a) Vesicles incubated in culture medium containing DMSO exhibit a normal morphological structure; (panel b) Metacestodes 
incubated in culture medium containing 40 μM 3-BrPA exhibit the loss of turgor, collapse of the vesicles, and detachment of the germinal layer from 
the laminated layer. LL: laminated layer, GL: germinal layer.
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noticeable damages: only residual cellular materials could 
be observed in many parts of the germinal layer tissues 
and in some regions, the germinal layers detached from 
the laminated layer (Figures 3B, C). After 120 h of incu-
bation with 3-BrPA, the microtriches shortened and 
reduced dramatically, and even disappeared in most parts 
of the tegument (Figures 4C, D). The arrangement of the 
germinal layer became loose and largely filled with vacu-
oles. Furthermore, some regions of the germinal layer 
exhibited electron-dense mitochondria, suggesting that 
the parasites were metabolically impaired during the 
treatment (Figure 4D).
Treatment of E. multilocularis infected mice with 3‑BrPA
To investigate the in  vivo therapeutic effect of 3-BrPA, 
BALB/c mice were intraperitoneally infected with E. 
multilocularis metacestodes and 8  weeks later admin-
istrated orally with ABZ (200  mg/kg/day) and 3-BrPA 
(25 mg/kg twice a week) respectively. After 6 weeks treat-
ment, metacestode tissues were isolated from each of the 
experimental mice and the parasite weights were deter-
mined (Figure 5). Kruskal–Wallis analysis indicated a sig-
nificant reduction of the wet weights of the metacestodes 
in both 3-BrPA (0.729 ± 0.256  g) and ABZ treated mice 
(0.477 ± 0.222  g) compared to those in the untreated 
group (1.860 ± 0.557 g). Although ABZ treatment seemed 
slightly more efficient than 3-BrPA, the difference in 
reduction of parasite weight did not show statistical sig-
nificance (p = 0.768). Furthermore, no death and obvious 
adverse effects were observed in the treated mice.
Cytotoxicity of 3‑BrPA on human hepatocytes
The cytotoxicity of 3-BrPA and ABZ was assessed on 
human hepatocytes by MTT assay. In this assay, the cells 
were treated with a concentration series (5, 10, 20, 40, 
80, 100, 160 and 200 μM) for 48 h (Figure 6). 3-BrPA and 
ABZ exhibited cytotoxicity in a concentration-depend-
ent manner. At 5  μM, 11.6 ± 3.61% and 14.33 ± 8.15% 
human hepatocytes were inhibited by 3-BrPA and ABZ 
respectively. When the concentration increased to 
200 μM, the inhibition of the hepatocyte viability reached 
85.4 ± 1.06% by 3-BrPA and 87.7 ± 0.43% by ABZ. 
The  IC50 value of 3-BrPA in human hepatocytes was 
87.84 μM, which was higher than ABZ (38.7 μM). How-
ever, 3-BrPA at the effective dose against E. granulosus 
protoscoleces and E. multilocularis metacestodes did not 
show significant toxicity to human hepatocytes as ABZ 
did.
Toxicology of 3‑BrPA in mice
To investigate the in  vivo toxicity of 3-BrPA, BALB/c 
mice were treated with 3-BrPA for 6 weeks. Table 1 pre-
sents the results of ALT, AST, TP, ALB, urea, CREA, ALP, 
GGT, TBIL, and DBIL levels in the serum of the mice 
after treatment. A significant increase (p = 0.033) in the 
level of AST was observed in the mice treated with ABZ 
Figure 3 SEM of E. multilocularis metacestodes incubated 
in vitro with 3‑BrPA. A Metacestodes incubated in culture medium 
containing DMSO served as controls. Note that the metacestode 
has a typical structure with an intact germinal layer. LL: laminated 
layer, GL: germinal layer. B, C The metacestodes incubated with 
40 μM 3-BrPA for 120 h show the germinal layer detached from the 
laminated layer and the loss of cellular integrity of the germinal layer.
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compared with the untreated control group. In addition, 
ABZ treated mice showed a reduction of TP (p = 0.049) 
and ALB levels (p = 0.044). In contrast, no significant dif-
ference of the above biochemical analysis items was seen 
in 3-BrPA treated mice compared with the untreated 
control mice. These tests indicate no obvious effects on 
the liver and kidney function in the 3-BrPA treated mice. 
Histopathological examinations of the liver and the kid-
ney in the treated mice confirmed the above results (Fig-
ure  7). The liver of ABZ treated mice exhibited distinct 
pathological changes: the spotty and focal necrosis, the 
hepatocyte edema, a number of inflammatory cells such 
as lymphocytes, the neutrophils infiltration, the dilation 
of partial portal area bile ducts, and the proliferation of 
fibrous connective tissue (Figure  7A). The histopatho-
logical examination in the kidney of ABZ treated mice 
revealed that the renal interstitium was hyperemic, and 
renal tubular epithelial cells swelled and had granular 
degeneration (Figure 7B) while the 3-BrPA treated mice 
did not show specific histopathological changes and inju-
ries in either liver (Figure 7A) or kidney (Figure 7B).
Discussion
In human or other intermediate hosts, the larval stage of 
Echinococcus depends on glycolysis for energy produc-
tion and intermediates for other metabolic processes [22, 
23] which implies that inhibition of glycolysis may prefer-
entially eliminate the Echinococcus metacestodes. This is 
Figure 4 TEM of E. multilocularis metacestodes incubated in vitro with 3‑BrPA. A, B The metacestodes of DMSO control show an intact 
morphology. LL: laminated layer, GL: germinal layer, Teg: tegument, Uc: undifferentiated cells, Gly: glycogen storage cells. The arrows indicate 
microtriches originating from the tegument and protruding into the germinated layer. C, D The metacestodes incubated with 40 μM 3-BrPA for 
120 h show severe structural damages. The microtriches are shortened and reduced dramatically and even disappeared in most parts of the 
tegument. The germinal layer tissues show degeneration, largely filled with vacuoles (black arrows) and electron-dense mitochondria (mi).
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the first study examining the potential therapeutic impli-
cations of the glycolytic inhibitors on E. granulosus and E. 
multilocularis. In the present study, we investigated the 
in vitro and in vivo effects of several glycolytic inhibitors, 
such as 3-BrPA, ornidazole, clorsulon, sodium oxamate 
and NA-P2, against E. granulosus and E. multilocularis.
Ornidazole, as one of the nitroimidazole agents 
against anaerobes and protozoa, is used for the treat-
ment of a variety of diseases, including intestinal amoe-
biasis, amoebic liver abscesses, anaerobic infections, 
giardiasis, and trichomoniasis [38–40]. Clorsulon is an 
aminobenzoldisulfonamide fasciolicide used in veteri-
nary medicine [28]. CLS has been successfully applied in 
triclabendazole-resistant fascioliasis of sheep [41, 42]. It 
has been reported that the trematocidal effects of ornida-
zole and clorsulon depend on the inhibition of glycolytic 
enzymes phosphoglycerate kinase (PGK) and phospho-
glyceratmutase (PGM) required by the trematodes for 
glycolysis [43, 44]. Oxamate is an established inhibitor of 
lactate dehydrogenase (LDH) via competition with pyru-
vate for the binding site on the enzyme. This compound 
has been recently proposed to be a promising anticancer 
drug that targets glycolysis [29–31]. 2,6-dihydroxynaph-
thalene (NA-P2) is an irreversible competitive inhibitor of 
hydroxynaphthaldehyde phosphate and exhibits a highly 
selective effect against the glycolytic enzyme fructose 
1,6-bisphosphate aldolase (ALDO) from Trypanosoma 
brucei [32] and rabbit muscle [45]. 3-BrPA, a halogen-
ated analog of pyruvic acid which exploits alkylating 
properties, is a potent inhibitor of hexokinase (HK) and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
and effectively inhibits glycolysis [24–26]. It is effective 
against a wide variety of tumors in pre-clinical studies 
without apparent toxicity or recurrence [46] and shows 
promise in human cases [47], indicating that 3-BrPA is a 
fast, promising, specific, and effective anti-cancer agent. 
Moreover, 3-BrPA has also exhibited antiparasitic activity 
against Trypanosoma brucei [48], Toxoplasma gondii [49] 
and Schistosoma mansoni [50].
In our in  vitro results, at an initial concentration of 
40  μM, all of the selected glycolytic inhibitors showed 
considerable effects (the percentage of dead proto-
scoleces was over 65% after 7 days of treatment) against 
Figure 5 Results of in vivo treatment of E. multilocularis‑infected 
mice with 3‑BrPA and ABZ. The box plots indicate the distribution 
of parasite weights in different treatment groups. Significant 
reductions of parasite weights in relation to the untreated control 
group were achieved by treatment with 3-BrPA and ABZ. Although 
ABZ treatment was slightly more efficient than 3-BrPA, the difference 
did not show statistical significance (p = 0.768).
Figure 6 Cytotoxicity of 3‑BrPA and ABZ on human hepatocytes. 
Cells were grown to confluence and incubated with 5, 10, 20, 40, 80, 
100, 160 and 200 μM drugs for 48 h. Assessment was made by MTT 
reduction assay. Values are presented as percentages relative to the 
values for the untreated control group. *p < 0.05 vs. ABZ incubation.
Table 1 Effect of 3-BrPA on biochemical parameters of 
BALB/c mice after 6 weeks of oral administration 
Data given as Mean ± SD of seven animals.
* Value significantly differs at 95% levels of significance (p < 0.05) for ABZ vs. 
untreated control.
Parameters Untreated ABZ treated 3‑BrPA treated
TBIL (μM/L) 2.257 ± 0.232 2.071 ± 0.437 2.25 ± 0.206
DBIL (μM/L) 1.157 ± 0.396 1.000 ± 0.346 1.267 ± 0.359
IBIL (μM/L) 1.100 ± 0.227 1.071 ± 0.281 0.983 ± 0.380
TP (g/L) 57.786 ± 1.89 54.900 ± 2.196* 58.65 ± 1.447
ALB (g/L) 32.257 ± 1.011 30.942 ± 0.972* 32.667 ± 0.624
GLB (g/L) 25.529 ± 2.175 23.957 ± 1.987 25.983 ± 1.061
ALP (U/L) 92.571 ± 9.256 118.000 ± 45.997 95.167 ± 14.554
ALT (U/L) 26.833 ± 7.151 41.429 ± 19.617 35.717 ± 10.517
AST (U/L) 115.500 ± 18.355 148.000 ± 27.475* 129.167 ± 8.783
GGT (U/L) 1.543 ± 0.475 1.614 ± 0.706 1.267 ± 0.269
UREA (mM/L) 9.711 ± 1.249 9.154 ± 1.847 10.330 ± 1.492
CREA (μM/L) 27.886 ± 4.362 29.714 ± 3.862 28.050 ± 2.862
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E. granulosus (Figure  1). In E. multilocularis metaces-
todes, each of the inhibitors could result in metaces-
tode damages and loss of viability demonstrated by the 
increased EmAP activity in culture medium (Figure  2). 
According to our research results, the actions of these 
agents against both E. granulosus protoscoleces and E. 
multilocularis metacestodes are most probably exerted, 
as glycolytic inhibitors, by inhibiting the activities of gly-
colytic enzymes such as PGK, PGM, LDH, ALDO, HK 
and GAPDH. Among these inhibitors, 3-BrPA exhibited 
the highest activity against Echinococcus. In order to 
assess the anti-Echinococcus effect of 3-BrPA as a glyco-
lysic inhibitor, ABZ and NTZ were used as positive con-
trols. ABZ is one of the two drugs licensed for treatment 
of human Echinococcosis [11], and NTZ that exhibits a 
high parasitocidal activity in  vitro against Echinococ-
cus and therefore always serves as an efficient positive 
in vitro control to investigate the anti-Echinococcus activ-
ity of agents [51]. In the experiment, 3-BrPA exhibited a 
more efficacious effect than ABZ, and as efficacious as 
NTZ although their drug targets were completely differ-
ent [52, 53].
The reason why 3-BrPA has a more active effect against 
Echinococcus than other selected glycolytic inhibitors 
might be due to the enzymes functioned by 3-BrPA. 
It has been documented that 3-BrPA prevents glucose 
from entering glycolysis by inhibiting HK [54]. As is 
well known, HK is the first one of a number of enzymes 
involved in glycolysis and more importantly, is a cru-
cial rate-limiting enzyme that exerts main control on 
glycolytic flux. There are studies that have reported the 
inhibitory effects of 3-BrPA on T. brucei due to blockade 
of the GAPDH enzyme [55]. Thus, 3-BrPA may negatively 
affect the enzymatic function of GAPDH by pyruvylation 
and lead to Echinococcus death. Moreover, the 3-BrPA-
mediated inhibition of HK can also impair the pentose 
phosphate pathway (PPP) and result in a reduction of 
ribose 5-phosphate synthesis that is crucial for parasite 
anabolism. At the same time, the inhibition of GAPDH 
can dampen the levels of its downstream-metabolite 
3-phosphoglycerate and result in reductions of lipids 
and amino acids. Thus, it is indicated that the profound 
efficacy of 3-BrPA against Echinococcus may depend 
not only on the depletion of the ATP pool, but also the 
reduction of important intermediates of glycolysis for 
other metabolic processes. While other selected glyco-
lytic inhibitors only dampen the downstream enzymes in 
the glycolysis pathway rather than HK.
The assay of concentration series of 3-BrPA demon-
strated that the anti-Echinococcus effect of 3-BrPA was 
both dose- and time-dependent and was also highly 
active even at low concentrations. Moreover, like the par-
asitocidal agent NTZ, 3-BrPA exerted destructive effects 
rapidly on protoscoleces. Even at a lower concentration 
of 10 μM, it could kill 67% protoscoleces within 4 days. 
In addition, for treatment of metacestodes, 3-BrPA trig-
gered a fast and dramatic increase in EmAP activity and 
distinct morphological alterations within 36 h compared 
with the ABZ treatment (Figure  2). This rapid action of 
3-BrPA was also reported in T. gondii by de Lima et  al. 
[49].
Figure 7 Histopathological examination of liver and kidney in 3‑BrPA treated mice. When the mice were sacrificed, liver and kidney were 
collected and fixed in 10% of neutral formaldehyde and embedded in paraffin for HE staining. A liver; B kidney.
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In the in vivo experiment, 3-BrPA-treated mice showed 
a statistically significant reduction in parasite weight 
compared to the untreated control, but not to ABZ treat-
ment (p = 0.768). The reason for this might be the admin-
istration frequency of twice a week with 3-BrPA, which is 
much less than the daily treatment of ABZ. Although the 
treatment of 3-BrPA (25  mg/kg twice a week) exhibited 
a slightly less efficient activity than ABZ against meta-
cestodes (in spite of no statistical difference), the in vivo 
toxicity assay showed almost no toxicity to the liver and 
kidney in the treated mice. In contrast, ABZ treated mice 
showed significant abnormalities in liver function, such 
as the reduction of TP and ALB levels and the increase 
in AST levels (Table 1 and Figure 7), accompanied with 
distinct pathological changes in the liver and kidney ver-
sus the untreated control, which was also consolidated 
by reports in human patients treated with ABZ as well 
[10, 11]. The levels of ALT, AST, TP, ALB, ALP, GGT, 
TBIL and DBIL are common markers for hepatic and bil-
iary functionality. When the liver is damaged, the levels 
of serum ALT, AST, ALP, GGT, TBIL and DBIL will be 
increased, while those of TP and ALB will be decreased. 
Likewise, the serum levels of urea and CREA are com-
mon markers for kidney functions, and when glomeru-
lar filtration function is impaired, urea and CREA levels 
will be increased. Certainly, the significant difference of 
toxicity might be due to the same reason of the different 
administration frequency between these two drugs. How-
ever, if it is taken into consideration that 3-BrPA exhib-
ited a higher  IC50 value (87.84 μM) than ABZ (38.7 μM) 
in the in vitro cytotoxicity assay, and at the effective dose 
against E. granulosus protoscoleces and E. multilocularis 
metacestodes, 3-BrPA did not show significant toxicity to 
human hepatocytes, the conclusion can be easily inter-
preted. In addition, our result is also supported by a study 
in mouse hepatocellular carcinoma which highlights the 
ability of 3-BrPA to eradicate cancer cells without causing 
significant toxicity to normal liver tissue or recurrence 
[56]. As is well known that in 70% of CE patients and in 
nearly 100% of AE patients, the parasite lesion occurs 
in the liver, leading to severe impairment of the liver. 
Therefore, in comparison to ABZ, the nearly non-toxic 
property of 3-BrPA treatment to the liver indicates that 
3-BrPA might be a promising alternative to ABZ in the 
treatment of echinococcosis.
In conclusion, in the present study, we demonstrate for 
the first time that the glycolytic inhibitors exhibit effec-
tive in  vitro activity against both E. granulosus and E. 
multilocularis. The in  vivo results of 3-BrPA also con-
solidate the anti-AE effect. Hence, implication of the gly-
colytic inhibitors might be a novel chemotherapeutical 
option of echinococcosis and glycolytic enzymes might 
be valuable and promising drug targets in Echinococcus. 
Furthermore, 3-BrPA, exhibiting a profound activity 
against Echinococcus and no host toxicity both in  vitro 
and in vivo, will be a promising drug for the treatment of 
echinococcosis and worthy of further investigation.
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